17/05/2023 ESTEVE REPORTS SIGNIFICANT GROWTH IN 2022 AND CONTINUES TO ADVANCE TOWARDS ITS VISION OF BECOMING AN INTERNATIONAL SPECIALTY PHARMA COMPANY Read more
07/03/2023 ESTEVE BRINGS TO MARKET THE FIRST INHALED RESCUE TREATMENT DESIGNED TO CONTROL OFF EPISODES IN PARKINSON’S DISEASE¹ Read more
03/11/2022 PERE ARAGONÉS, PRESIDENT OF THE GOVERNMENT OF CATALONIA, VISITS ESTEVE’S MAIN INDUSTRIAL PLANT Read more
26/05/2022 ESTEVE REINFORCES ITS COMMITMENT TO SUSTAINABILITY IN ALL THREE DIMENSIONS: SOCIAL, ENVIRONMENTAL AND ECONOMIC Read more
18/10/2021 ESTEVE ANNOUNCES FDA APPROVAL OF A NOVEL CO-CRYSTAL FORM OF CELECOXIB AND TRAMADOL FOR THE MANAGEMENT OF ACUTE PAIN Read more
14/10/2021 FOLLOWING IN THE WAKE OF COVID-19, MYOPIA WILL BE THE NEXT PANDEMIC TO EMERGE, ESPECIALLY AMONG CHILDREN AND YOUNG PEOPLE Read more
03/06/2021 BY 2023, 100% OF ESTEVE’S COMMERCIAL FLEET WILL BE PLUG-IN HYBRID AND ELECTRIC CARS Read more
03/05/2021 ESTEVE AND KOWA PHARMACEUTICALS AMERICA ENTER INTO AN EXCLUSIVE LICENSE AND COMMERCIALIZATION AGREEMENT FOR RIGHTS TO E-58425 FOR THE POTENTIAL MANAGEMENT OF ACUTE PAIN1-9 IN THE UNITED STATES8,9 Read more
30/04/2021 PROFARMA HAS ONCE AGAIN RATED ESTEVE’S RESEARCH AND INNOVATION ACTIVITY AS "EXCELLENT" Read more
12/02/2021 ESTEVE IS COLLABORATING IN A CLINICAL TRIAL ON EARLY TREATMENT OF PATIENTS WITH MILD COVID-19 SYMPTOMS AND CONFIRMED INFECTION Read more
28/10/2020 IT IS POSSIBLE TO MAINTAIN THE LEVEL OF INNOVATION AND THE SUSTAINABILITY OF THE NHS AT THE SAME TIME Read more
30/07/2020 ESTEVE COLLABORATES WITH NUTRICIÓ SENSE FRONTERES AND FESBAL IN THEIR EFFORTS TO HELP UNDERPRIVILEGED FAMILIES BY DONATING 6,800 MENUS Read more
09/07/2020 ESTEVE AND LEITAT ANNOUNCE STRATEGIC PARTNERSHIP TO COLLABORATE IN RESEARCH AND DEVELOPMENT Read more
28/04/2020 ESTEVE ADDS ITS WEIGHT TO THE FIGHT AGAINST THE PANDEMIC THROUGH DONATIONS AND RESEARCH COLLABORATIONS Read more
03/04/2020 ESTEVE QUÍMICA REVAMPS ITS WEBSITE IN ORDER TO CONTINUE TO BE A KEY SUPPLIER FOR THE HEALTHCARE INDUSTRY Read more
18/02/2020 FALLS ARE THE PRIMARY CAUSE OF TRAUMATIC SPINAL CORD INJURY, OUTNUMBERING ROAD TRAFFIC ACCIDENTS Read more
08/01/2020 ESTEVE ACQUIRES GERMAN PROPRIETARY, SPECIALTY, HOSPITAL-FOCUSED COMPANY RIEMSER AND EXPANDS ITS PRESENCE IN EUROPE Read more
23/12/2019 TOWA PHARMACEUTICAL CO., LTD. REACHES AN AGREEMENT WITH ESTEVE TO ACQUIRE ESTEVE’S GENERIC DIVISION, PENSA INVESTMENTS Read more
31/07/2019 THE UDG PROVES THE EFFECT OF AN ESTEVE DRUG THAT PREVENTS SPINAL CORD INJURY PAIN Read more
10/04/2019 THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’ Read more
09/04/2019 PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES Read more
03/04/2019 ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER Read more
21/01/2019 POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN Read more
11/10/2018 NURSES OFFER CARE AND PREVENTION OF DRY EYE, A CONDITION THAT AFFECTS 60% OF PEOPLE OLDER THAN 45 YEARS Read more
08/10/2018 ONE THIRD OF DIABETIC PATIENTS ARE OLDER THAN 75 YEARS AND THEIR HYPOGLYCEMIA GOES UNDETECTED IN 1 OUT OF 5 CASES Read more
17/05/2018 PHARMACEUTICAL ASSISTANCE IN SOCIO-MEDICAL CENTERS IS KEY TO THE CONTINUUM OF CARE PROVIDED TO MULTICONDITION PATIENTS Read more
06/03/2018 80% OF PATIENTS WITH COPD AND 50% OF PATIENTS WITH CHRONIC PAIN ARE POORLY TREATED Read more
26/02/2018 IN DIABETES, THE USE OF E-HEALTH IS MORE WIDESPREAD AMONG PATIENTS THAN AMONG PROFESSIONALS Read more
20/02/2018 PATIENT ACCESS TO CARDIAC REHABILITATION PROGRAMS IS UNEQUAL ACROSS AUTONOMOUS COMMUNITIES Read more
13/02/2018 SECOND EDITION OF HEARTBEATS THAT ADD UP SUCCESSFULLY COMPLETED: 100,000 KILOMETERS COVERED AND 30 NEW DEFIBRILLATORS Read more
22/01/2018 THE DEPARTMENT OF HEALTH AND ESTEVE WILL CONDUCT A POPULATION-BASED HEALTH LITERACY SURVEY Read more
Press Contact For more information please contact us: Irene Simón Head of Global External Communications & ESG + 34 93 446 60 00isimon@esteve.com